Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943) is a single molecule that activates three receptors simultaneously—those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This expansion follows a plausible logic: with each additional mechanism of action, the average weight loss in the studies increased—from GLP-1 alone, through GLP-1 plus GIP, to the triple combination. Retatrutide is the most advanced representative of this new class to date and attracted significant attention in 2025/2026 with the first Phase 3 results from the TRIUMPH program.
Jetzt beitreten
